III
Beyond's analysis on III
- — Akeso initiates Phase III perioperative trial of cadonilimab in colon cancer, advancing a novel bispecific immuno‑oncology candidate toward potential regulatory approval
- — FDA’s approval of Roche’s Tecentriq for adjuvant colon cancer expands immunotherapy options and promises a new revenue stream for the drug
- — Tallinn harbour’s Q3 2026 cargo volumes slipped while passenger traffic rose modestly, highlighting divergent freight and travel trends
- — TextMagic posts 12% YoY revenue growth in Q3 2026, reaching €3.6 million
- — Akeso initiates first patient enrollment in global Phase III trial comparing its PD-1/LAG-3 bispecific cadonilimab to nivolumab for first-line gastric cancer
- — XTEND advances to Phase III of U.S. SOCOM modular drone program, reinforcing its position in the drone dominance market
- — Akeso secures major clinical spotlight at ESMO 2026 with breakthrough Phase III biliary tract cancer survival data
- — Antengene initiates pivotal Phase III CLINCH-3 trial of ATG-022, advancing its oncology pipeline
- — Kelun-Biotech reports Phase III results for its HER2-targeted antibody-drug conjugate trastuzumab botidotin versus the established T-DM1 in HER2-positive breast cancer, with findings published in the Journal of Clinical Oncology
- — Phase III MAVERICK trial shows MRI‑only surveillance can replace prophylactic cranial irradiation in small‑cell lung cancer, cutting treatment costs and adverse events
- — Tam-Peli achieves significant survival improvement in Phase III trials for relapsed small-cell lung cancer
- — Risvutatug Rezetecan cuts death risk by 54% versus topotecan in relapsed small-cell lung cancer, signaling a potential new standard of care
Recent news mentioning III
- — First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
- — 2026. aasta III kvartali ja 9 kuu auditeerimata majandustulemused
- — ASi Tallinna Sadam 2026. aasta III kvartali ja 9 kuu tegevusmahud
- — FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
- — EXPLORA III MAKES MAIDEN CALL TO NEW YORK CITY
- — Saol Therapeutics Announces Completion of Enrollment in Pivotal Phase III BEACON Trial of SL1002 for the Treatment of Chronic Pain Related to Osteoarthritis of the Knee
- — AnnJi Pharmaceutical fait passer l'AJ201 à l'étude pivot de phase III ROMA-KD pour le traitement de l'atrophie musculaire spinale et bulbaire (SBMA)
- — TextMagic grupi müügitulemused 2026. aasta III kvartalis
- — Leonardo DRS Completes Training and Delivery of INOD Block III Thermal Weapon Sights for the Australian Army
- — AS-i Tallink Grupp 2026. aasta septembri ja III kvartali statistika
- — Снижение массы тела на 19,3 % к 48-й неделе -- данные исследования фазы III препарата Olatorepatide, двойного селективного агониста ГПП-1/ГИП компании Hansoh, представлены на EASD
- — Pokles hmotnosti o 19,3 % v 48. týždni: spoločnosť Hansoh prezentovala na EASD III. fázu štúdie o olatorepatide, duálnom funkčne selektívnom agonistovi receptorov GLP-1 a GIP